Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.3K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Drug Therapy01:28

Drug Therapy

401
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
401

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom.

British journal of haematology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Cambridge neuroscience symposium: Interventions and recovery.

Brain and neuroscience advances·2025
Same author

Ageing and remyelination failure in people with multiple sclerosis.

Brain : a journal of neurology·2025
Same author

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.

Brain : a journal of neurology·2025
Same journal

Hepatitis B Infection-Associated Aortoarteritis.

Annals of Indian Academy of Neurology·2026
Same journal

Correspondence- Muscle Magnetic Resonance Imaging Phenotyping and Pattern Recognition in Genetically Confirmed Myopathies: A Large-Cohort Study from the Indian Subcontinent.

Annals of Indian Academy of Neurology·2026
Same journal

STAC3-Related Congenital Myopathy (CMYP13) in an Adult Indian Patient: Expanding the Geographic Spectrum to India.

Annals of Indian Academy of Neurology·2026
Same journal

A Prospective Study on Autonomic Functions in Idiopathic Inflammatory Myopathies: The AFIIM Study.

Annals of Indian Academy of Neurology·2026
Same journal

Magnetic Resonance Imaging Findings During Encephalopathic Crisis in Glutaric Aciduria Type 1: Expanding the Radiologic Phenotype.

Annals of Indian Academy of Neurology·2026
Same journal

Thyroid Function and Cognitive Health in Older Adults: Insights from the LASI-DAD Study.

Annals of Indian Academy of Neurology·2026
See all related articles

Related Experiment Video

Updated: Mar 30, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K

Newer therapies for multiple sclerosis.

Alasdair Coles1

  • 1Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Annals of Indian Academy of Neurology
|November 6, 2015
PubMed
Summary
This summary is machine-generated.

Newer multiple sclerosis immunotherapies offer improved efficacy but carry greater risks. Physicians must carefully select treatments and monitor patients for disease breakthrough or adverse effects.

Keywords:
Multiple sclerosisNewer drugsdisease burdenefficacysafety

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.4K

Related Experiment Videos

Last Updated: Mar 30, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.4K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) therapies have evolved significantly from 1990s injectables.
  • Newer immunotherapies provide enhanced efficacy and tolerability but introduce novel risks.

Purpose of the Study:

  • To guide physicians in navigating the complex landscape of emerging MS treatments.
  • To inform the strategic selection between "escalation" and "induction" treatment approaches.
  • To emphasize the importance of vigilant monitoring for disease activity and adverse events.

Main Methods:

  • Comparative analysis of existing and emerging MS immunotherapies.
  • Review of treatment strategies including escalation and induction paradigms.
  • Discussion of risk-benefit profiles for various MS medications.

Main Results:

  • Novel immunotherapies demonstrate superior efficacy and tolerability compared to older treatments.
  • Emerging MS drugs like daclizumab and ocrelizumab are anticipated.
  • Significant risks associated with newer MS therapies necessitate careful patient management.

Conclusions:

  • Physicians require a framework to integrate new MS therapies into treatment strategies.
  • Vigilance for disease breakthrough and adverse effects is crucial during MS treatment.
  • Personalized treatment selection and ongoing monitoring are key for managing multiple sclerosis effectively.